

Retinal Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/R663041229C7EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: R663041229C7EN

Abstracts

The 7 major retinal edema markets reached a value of US\$ 5.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 13.5 Billion by 2034, exhibiting a growth rate (CAGR) of 7.84% during 2024-2034.

The retinal edema market has been comprehensively analyzed in IMARC's new report titled "Retinal Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Retinal edema refers to the accumulation of fluid in the layers of the retina, the light-sensitive tissue lining the back of the eye. This condition is often a result of various underlying issues, such as diabetic retinopathy, macular degeneration, retinal vein occlusion, or inflammatory diseases. The symptoms of the illness can vary but commonly include blurred or distorted vision, decreased visual acuity, and the perception of floating spots or floaters. Individuals suffering from the ailment might also experience changes in color perception and difficulty with low-light vision. Since these symptoms can overlap with other eye conditions, an accurate diagnosis is crucial. The diagnosis of retinal edema typically involves a comprehensive eye examination, which may include visual acuity tests and optical coherence tomography (OCT) to visualize retinal layers and fluid accumulation. A healthcare provider will also conduct fluorescein angiography to evaluate blood flow within the retina and detect any abnormalities.

The increasing cases of diabetic retinopathy, macular degeneration, and retinal vein occlusion, which can cause microvascular abnormalities and disruptions in the retinal barrier, are primarily driving the retinal edema market. In addition to this, the inflating utilization of effective therapeutic approaches, including anti-VEGF agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), etc., to effectively

manage the condition and mitigate further visual impairment, is creating a positive outlook for the market. Moreover, the widespread adoption of advanced retinal imaging techniques, that enable precise visualization of retinal structures and facilitate early detection of edema is also bolstering the market growth. Apart from this, the rising usage of personalized medicine, wherein treatment strategies are tailored to individual patient profiles, including their genetic predispositions and response to therapies, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of vitreoretinal surgery, owing to its numerous advantages, such as enhancing patient's quality of life, reducing macular thickness, and preventing associated complications, is also augmenting the market growth. Furthermore, the escalating demand for regenerative therapies, encompassing stem cell-based approaches and gene editing techniques, to help in addressing the root causes of the illness, is expected to drive the retinal edema market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the retinal edema market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for retinal edema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the retinal edema market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the retinal edema market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the retinal edema market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current retinal edema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the retinal edema market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the retinal edema market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the retinal edema market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of retinal edema across the seven major markets?

What is the number of prevalent cases (2018-2034) of retinal edema by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of retinal edema by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with retinal edema across the seven major markets?

What is the size of the retinal edema patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of retinal edema?

What will be the growth rate of patients across the seven major markets?

Retinal Edema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for retinal edema drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the retinal edema market?

What are the key regulatory events related to the retinal edema market?

What is the structure of clinical trial landscape by status related to the retinal edema market?

What is the structure of clinical trial landscape by phase related to the retinal edema market?

What is the structure of clinical trial landscape by route of administration related to the retinal edema market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 RETINAL EDEMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 RETINAL EDEMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 RETINAL EDEMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?????2018-2034?)
 - 7.2.4 Epidemiology by Gender (?????2018-2034?)
 - 7.2.5 Diagnosed Cases (?????2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?????2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?????2018-2034?)
 - 7.3.4 Epidemiology by Gender (?????2018-2034?)
 - 7.3.5 Diagnosed Cases (?????2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?????2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?????2018-2034?)
 - 7.4.4 Epidemiology by Gender (?????2018-2034?)
 - 7.4.5 Diagnosed Cases (?????2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?????2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?????2018-2034?)
 - 7.5.4 Epidemiology by Gender (?????2018-2034?)
 - 7.5.5 Diagnosed Cases (?????2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?????2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?????2018-2034?)
 - 7.6.4 Epidemiology by Gender (?????2018-2034?)
 - 7.6.5 Diagnosed Cases (?????2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?????2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?????2018-2034?)

- 7.7.4 Epidemiology by Gender (?????2018-2034?)
- 7.7.5 Diagnosed Cases (?????2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?????2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?????2018-2034?)
 - 7.8.4 Epidemiology by Gender (?????2018-2034?)
 - 7.8.5 Diagnosed Cases (?????2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?????2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?????2018-2034?)
 - 7.9.4 Epidemiology by Gender (?????2018-2034?)
 - 7.9.5 Diagnosed Cases (?????2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?????2018-2034?)

8 RETINAL EDEMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 RETINAL EDEMA - UNMET NEEDS

10 RETINAL EDEMA - KEY ENDPOINTS OF TREATMENT

11 RETINAL EDEMA - MARKETED PRODUCTS

- 11.1 List of Retinal Edema Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Lucentis (Ranibizumab) - Genentech/Novartis Ophthalmics
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Eylea (Aflibercept) - Bayer/Regeneron Pharmaceuticals/Sanofi
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Ozurdex (Dexamethasone ophthalmic) - AbbVie
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Vabysmo (Faricimab) - Roche
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Byooviz (Ranibizumab biosimilar) - Samsung Bioepis
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 RETINAL EDEMA - PIPELINE DRUGS

- 12.1 List of Retinal Edema Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 MYL-1701P- Momenta Pharmaceuticals/Viatris
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 KSI 301 - Kodiak Sciences
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 APX3330 - Ocuphire Pharma
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 THR-149 - Oxurion
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 OXU-001 - Oxular
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. RETINAL EDEMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. RETINAL EDEMA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 RETINAL EDEMA - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Retinal Edema - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)

- 15.2.2 Retinal Edema - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Retinal Edema - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Retinal Edema - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Retinal Edema - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Retinal Edema - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Retinal Edema - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Retinal Edema - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Retinal Edema - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Retinal Edema - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Retinal Edema - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Retinal Edema - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Retinal Edema - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Retinal Edema - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Retinal Edema - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)

- 15.7.2 Retinal Edema - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Retinal Edema - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Retinal Edema - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Retinal Edema - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Retinal Edema - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Retinal Edema - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Retinal Edema - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Retinal Edema - Access and Reimbursement Overview

16 RETINAL EDEMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 RETINAL EDEMA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 RETINAL EDEMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Retinal Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/R663041229C7EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R663041229C7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

